Guillain-Barré syndrome classification: Difference between revisions
No edit summary |
No edit summary |
||
(12 intermediate revisions by the same user not shown) | |||
Line 2: | Line 2: | ||
{{Guillain-Barré syndrome}} | {{Guillain-Barré syndrome}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{Fs}} | ||
==Overview== | ==Overview== | ||
Guillain Barre syndrome may be classified according to the underlying pathophysiology into four groups: [[Acute motor axonal neuropathy]] (AMAN), acute motor axonal neuropathy (AMAN), acute motor and sensory axonal neuropathy and [[Miller Fisher syndrome]]. | |||
==Classification== | ==Classification== | ||
=== | Guillain Barre syndrome may be classified according to the underlying pathophysiology into four groups:<ref name="pmid9818934">{{cite journal |vauthors=Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka KV, Swan AV |title=Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group |journal=Ann. Neurol. |volume=44 |issue=5 |pages=780–8 |date=November 1998 |pmid=9818934 |doi=10.1002/ana.410440512 |url=}}</ref><ref name="pmid5059983">{{cite journal |vauthors=Prineas JW |title=Acute idiopathic polyneuritis. An electron microscope study |journal=Lab. Invest. |volume=26 |issue=2 |pages=133–47 |date=February 1972 |pmid=5059983 |doi= |url=}}</ref><ref name="pmid7600081">{{cite journal |vauthors=Ho TW, Mishu B, Li CY, Gao CY, Cornblath DR, Griffin JW, Asbury AK, Blaser MJ, McKhann GM |title=Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies |journal=Brain |volume=118 ( Pt 3) |issue= |pages=597–605 |date=June 1995 |pmid=7600081 |doi= |url=}}</ref><ref name="pmid7224616">{{cite journal |vauthors=Prineas JW |title=Pathology of the Guillain-Barré syndrome |journal=Ann. Neurol. |volume=9 Suppl |issue= |pages=6–19 |date=1981 |pmid=7224616 |doi= |url=}}</ref><ref name="pmid9708542">{{cite journal |vauthors=Kuwabara S, Yuki N, Koga M, Hattori T, Matsuura D, Miyake M, Noda M |title=IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barré syndrome |journal=Ann. Neurol. |volume=44 |issue=2 |pages=202–8 |date=August 1998 |pmid=9708542 |doi=10.1002/ana.410440210 |url=}}</ref><ref name="pmid11026446">{{cite journal |vauthors=Ogawara K, Kuwabara S, Mori M, Hattori T, Koga M, Yuki N |title=Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan |journal=Ann. Neurol. |volume=48 |issue=4 |pages=624–31 |date=October 2000 |pmid=11026446 |doi= |url=}}</ref><ref name="pmid8572662">{{cite journal |vauthors=Griffin JW, Li CY, Ho TW, Tian M, Gao CY, Xue P, Mishu B, Cornblath DR, Macko C, McKhann GM, Asbury AK |title=Pathology of the motor-sensory axonal Guillain-Barré syndrome |journal=Ann. Neurol. |volume=39 |issue=1 |pages=17–28 |date=January 1996 |pmid=8572662 |doi=10.1002/ana.410390105 |url=}}</ref><ref name="pmid13334797">{{cite journal |vauthors=FISHER M |title=An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia) |journal=N. Engl. J. Med. |volume=255 |issue=2 |pages=57–65 |date=July 1956 |pmid=13334797 |doi=10.1056/NEJM195607122550201 |url=}}</ref><ref name="pmid8228822">{{cite journal |vauthors=Yuki N, Taki T, Inagaki F, Kasama T, Takahashi M, Saito K, Handa S, Miyatake T |title=A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure |journal=J. Exp. Med. |volume=178 |issue=5 |pages=1771–5 |date=November 1993 |pmid=8228822 |pmc=2191246 |doi= |url=}}</ref> | ||
=== | |||
{| | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Subtypes | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Explanation | |||
! | |||
! | |||
|- | |- | ||
! style="background: #DCDCDC; text-align: center;" |Acute Motor Axonal Neuropathy (AMAN) | ! style="background: #DCDCDC; text-align: center;" |Acute Motor Axonal Neuropathy (AMAN) | ||
Line 65: | Line 18: | ||
* The most common type (85-90%). | * The most common type (85-90%). | ||
* Prior infection can trigger it. | * Prior infection can trigger it. | ||
* Autoimmune disorder. | * [[Autoimmune disorder]]. | ||
* The target is schwann cell surface membrane or the myelin. | * The target is [[schwann cell]] surface membrane or the [[myelin]]. | ||
* Causes demyelination. | * Causes [[demyelination]]. | ||
* In electrodiagnostic tests we can see slowing of nerve conduction. | * In electrodiagnostic tests we can see slowing of nerve conduction. | ||
* In pathology we can see lymphocytic infiltration of peripheral nerves and macrophage invasion of myelin sheath and schwann cells. | * In pathology we can see [[Lymphocyte|lymphocytic]] infiltration of peripheral nerves and [[macrophage]] invasion of [[myelin sheath]] and [[Schwann cell|schwann cells]]. | ||
|- | |- | ||
!Acute Motor Axonal Neuropathy (AMAN) | ! style="background: #DCDCDC; text-align: center;" |Acute Motor Axonal Neuropathy (AMAN) | ||
| style="background: #F5F5F5;" | | |||
* It’s common among Chinese and Japanese people. | |||
* It can be triggered by C. jejuni. | |||
* It is associated with anti[[ganglioside]] [[antibodies]]. | |||
* [[Autoimmunity|Autoimmune]] disorder. | |||
* Target is [[Axon|axonal]] membrane. | |||
* Causes [[Axon|axonal]] degeneration in [[Motor neuron|motor neurons]]. | |||
* In electrodiagnostic study we can see reduction of compound muscle [[action potential]]. | |||
|- | |- | ||
! style="background: #DCDCDC; text-align: center;" |Acute motor and sensory axonal neuropathy | ! style="background: #DCDCDC; text-align: center;" |Acute motor and sensory axonal neuropathy | ||
| style="background: #F5F5F5;" | | | style="background: #F5F5F5;" | | ||
* The incidence rate is under 10%. | |||
* Causes [[Axon|axonal]] [[degeneration]]. | |||
* It is similar with [[Acute motor axonal neuropathy|AMAN]] but involves both motor and sensory [[Axon|axons]]. | |||
|- | |- | ||
! style="background: #DCDCDC; text-align: center;" |Miller Fisher syndrome | ! style="background: #DCDCDC; text-align: center;" |Miller Fisher syndrome | ||
| style="background: #F5F5F5;" | | | style="background: #F5F5F5;" | | ||
* Causes a clinical triad: [[ophthalmoplegia]], [[ataxia]] and [[areflexia]]. | |||
* Associated with [[ganglioside]] GQ1b [[antibody]]. | |||
|} | |} | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} |
Latest revision as of 15:49, 27 December 2018
Guillain-Barré syndrome Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Guillain-Barré syndrome classification On the Web |
American Roentgen Ray Society Images of Guillain-Barré syndrome classification |
Risk calculators and risk factors for Guillain-Barré syndrome classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.
Overview
Guillain Barre syndrome may be classified according to the underlying pathophysiology into four groups: Acute motor axonal neuropathy (AMAN), acute motor axonal neuropathy (AMAN), acute motor and sensory axonal neuropathy and Miller Fisher syndrome.
Classification
Guillain Barre syndrome may be classified according to the underlying pathophysiology into four groups:[1][2][3][4][5][6][7][8][9]
Subtypes | Explanation |
---|---|
Acute Motor Axonal Neuropathy (AMAN) |
|
Acute Motor Axonal Neuropathy (AMAN) |
|
Acute motor and sensory axonal neuropathy |
|
Miller Fisher syndrome |
|
References
- ↑ Hadden RD, Cornblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka KV, Swan AV (November 1998). "Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group". Ann. Neurol. 44 (5): 780–8. doi:10.1002/ana.410440512. PMID 9818934.
- ↑ Prineas JW (February 1972). "Acute idiopathic polyneuritis. An electron microscope study". Lab. Invest. 26 (2): 133–47. PMID 5059983.
- ↑ Ho TW, Mishu B, Li CY, Gao CY, Cornblath DR, Griffin JW, Asbury AK, Blaser MJ, McKhann GM (June 1995). "Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies". Brain. 118 ( Pt 3): 597–605. PMID 7600081.
- ↑ Prineas JW (1981). "Pathology of the Guillain-Barré syndrome". Ann. Neurol. 9 Suppl: 6–19. PMID 7224616.
- ↑ Kuwabara S, Yuki N, Koga M, Hattori T, Matsuura D, Miyake M, Noda M (August 1998). "IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barré syndrome". Ann. Neurol. 44 (2): 202–8. doi:10.1002/ana.410440210. PMID 9708542.
- ↑ Ogawara K, Kuwabara S, Mori M, Hattori T, Koga M, Yuki N (October 2000). "Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan". Ann. Neurol. 48 (4): 624–31. PMID 11026446.
- ↑ Griffin JW, Li CY, Ho TW, Tian M, Gao CY, Xue P, Mishu B, Cornblath DR, Macko C, McKhann GM, Asbury AK (January 1996). "Pathology of the motor-sensory axonal Guillain-Barré syndrome". Ann. Neurol. 39 (1): 17–28. doi:10.1002/ana.410390105. PMID 8572662.
- ↑ FISHER M (July 1956). "An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia)". N. Engl. J. Med. 255 (2): 57–65. doi:10.1056/NEJM195607122550201. PMID 13334797.
- ↑ Yuki N, Taki T, Inagaki F, Kasama T, Takahashi M, Saito K, Handa S, Miyatake T (November 1993). "A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure". J. Exp. Med. 178 (5): 1771–5. PMC 2191246. PMID 8228822.